- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.10. | Hiring for Resilience in Life Sciences Sales | ||
| 02.10. | Regulatory tracker: Camzyos wins pediatric nod at FDA | ||
| 02.10. | Teva, Samsung Bioepis deepen biosimilar bonds with new deal | ||
| 02.10. | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| 01.10. | Lilly dives deep into Foundayo's cardio perks in T2D, obesity | ||
| 01.10. | Taiho ph. 3 win sets up potential oral franchise expansion | ||
| 01.10. | Real Chemistry launches AI-powered MaestroHCP to conduct omnichannel campaigns | ||
| 01.10. | Asahi Kasei wraps years of global dealmaking into a single brand | ||
| 30.09. | Varda brings home $251M series D to fuel space-based drug manufacturing | ||
| 30.09. | Vanda lines up new expansion prospect for Hetlioz as FDA jet lag hearing looms | ||
| 30.09. | Hansoh's Tagrisso rival loses EU approval after AstraZeneca legal challenge | ||
| 30.09. | CSL Seqirus boasts bigger batch of flu vaccines ahead of US flu season | ||
| 30.09. | Alnylam drafts football veteran Pete Shaw for heart disease education push | ||
| 29.09. | NorthStar locks down $185M as radiopharmaceutical isotope, CDMO expansion plans advance | ||
| 29.09. | PhRMA locks in former House Majority Leader Cantor as next CEO | ||
| 29.09. | White House lays groundwork to reshore production of 86 essential medicines | ||
| 29.09. | Big Pharma's Big Brand: Regeneron's science-driven communications approach | ||
| 29.09. | Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan | ||
| 29.09. | US details rules for 0% specialty pharmaceutical tariff exemptions | ||
| 29.09. | Inizio Evoke names new leaders in media, AI and client accounts | ||
| 29.09. | Audien beams up William Shatner to boldly boost OTC hearing aid awareness | ||
| 29.09. | AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combos | ||
| 28.09. | BioNTech to close 3 sites in Germany after failed buyer search | ||
| 28.09. | Roche's Gazyva secures FDA nod for idiopathic nephrotic syndrome, extending autoimmune pivot | ||
| 28.09. | Eli Lilly's new initiative will take GLP-1s to lower-income nations |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.